By admin 
Cardiovascular disease (CVD) remains the leading cause of death globally, responsible for an estimated 17.9 million lives each year, according to the World Health Organization. In the United States, about 10% of adults aged 30-79 live with some form of cardiovascular disease, underscoring the critical importance of accurate risk assessment and timely primary prevention strategies. Heart attacks, strokes, and other adverse cardiovascular events are largely preventable, making the early identification of at-risk individuals a cornerstone of modern medicine. For decades, clinicians have relied on various risk assessment tools to guide preventive care, from lifestyle modifications to pharmacotherapy like statins. The advent of coronary artery calcium (CAC) scoring added a new dimension to this landscape, offering a direct glimpse into the arterial wall itself.
A coronary artery calcium scan operates on a straightforward principle: it identifies and quantifies calcified plaque within the coronary arteries. These calcium deposits are a hallmark of atherosclerosis, the hardening and narrowing of arteries due to plaque buildup. While calcium itself is not the immediate cause of a heart attack, its presence strongly indicates the extent of atherosclerotic disease. The resulting "calcium score," often reported using the Agatston scoring method, reflects the total amount of detectable calcified plaque. A score of zero indicates no detectable calcification and is generally associated with a very low risk of future cardiovascular events. Scores range upwards, with higher numbers (e.g., 1-100, 101-400, >400) correlating with a progressively greater burden of atherosclerosis and, consequently, a higher risk of future cardiovascular disease. The visual nature of the scan, providing a tangible image of disease, has resonated with both clinicians and patients, often serving as a powerful motivator for lifestyle changes and adherence to prescribed medications.
Before the widespread adoption of CAC scans, and still as the foundation of risk assessment, physicians utilize risk calculators that synthesize readily available clinical information. The American Heart Association’s (AHA) PREVENT calculator, for instance, estimates a person’s chance of developing cardiovascular disease over the next 10 or 30 years. PREVENT builds upon previous models like the ASCVD Risk Estimator, incorporating commonly available health information such as blood pressure, cholesterol levels (total, HDL, LDL), age, sex, smoking status, diabetes diagnosis, and whether a patient is receiving treatment for hypertension or using statins. It provides a comprehensive, albeit statistical, projection of an individual’s cardiovascular risk. PREVENT’s strength lies in its ability to be used broadly in primary care settings without specialized testing, making it an accessible and robust first-line tool for risk stratification.
The Northwestern Medicine study, published on August 26 in the prestigious journal JAMA, sought to understand how much additional information CAC scores truly provide when integrated with PREVENT. Researchers followed more than 6,000 adults aged 45 to 79 for a decade, drawing data from the Multi-Ethnic Study of Atherosclerosis (MESA). MESA is a landmark research study that has contributed significantly to our understanding of the prevalence, progression, and risk factors for subclinical cardiovascular disease and the progression to clinical cardiovascular disease. Its diverse cohort and rigorous methodology lend substantial weight to the Northwestern team’s findings.
At the beginning of the MESA study, each participant underwent both a coronary artery calcium scan and received a PREVENT estimate of their likelihood of experiencing a cardiovascular event within the subsequent 10 years. Researchers meticulously tracked actual health outcomes over the following decade. During this period, 6% of the participants experienced either a heart attack or a stroke. When the research team compared predictions that included CAC scores with those based on PREVENT alone, the overall improvement in predictive accuracy across the entire study population was modest. The model’s discrimination, a statistical measure of how effectively it distinguishes between people who will and will not experience a cardiovascular event, increased only slightly—from 0.73 using PREVENT alone to 0.75 when CAC scores were incorporated. This incremental gain, while statistically significant, suggests that for the average patient, the added benefit of a CAC scan on top of a well-performed PREVENT calculation might not be substantial enough to warrant universal screening.
However, the picture changed dramatically when researchers narrowed their focus to a specific subset of patients: those whose initial PREVENT scores placed them in the borderline or intermediate risk categories. These are individuals typically estimated to have a 10-year risk of heart disease between 3% and 9%. This group represents a clinical "gray area" where treatment decisions are often less clear-cut than for those at very low or very high risk. For these borderline and intermediate risk patients, including the coronary artery calcium score produced a far more meaningful and clinically actionable improvement in predicting future cardiovascular events.
"Coronary artery calcium scans are becoming more widely available and less expensive," said study senior author Dr. Nilay Shah, assistant professor of medicine in the division of cardiology at Northwestern University Feinberg School of Medicine. "Our findings suggest that not everyone necessarily needs or would benefit from a coronary artery calcium scan for the purpose of predicting risk of heart attack and stroke." Dr. Shah’s comments highlight a crucial point: in an era of increasing healthcare costs and potential over-medicalization, judicious use of diagnostic tools is paramount.
The study’s findings illuminate potential downsides of routinely using CAC scans when they are unlikely to alter a patient’s treatment plan. For instance, individuals already identified as low risk by PREVENT (e.g., a 10-year risk below 3%) are unlikely to have their management changed by a CAC score. Routinely performing a calcium scan in these individuals may result in unnecessary radiation exposure, which, while minimal, accumulates over a lifetime. It can also lead to incidental findings (e.g., small lung nodules) that require further, often costly and anxiety-inducing, follow-up tests with unclear clinical benefits. Conversely, for people already at high risk (e.g., a 10-year risk of 10% or more), statin therapy is generally recommended regardless of what a calcium scan shows. In these cases, the scan becomes redundant, adding to healthcare costs without changing the recommended primary prevention strategy. "Using calcium scans in people who are at high risk is likely to result in unnecessary testing because these individuals are recommended to start a statin regardless of what the calcium scan shows," Shah added.
The true value of the CAC scan, according to the Northwestern research, lies in its ability to reclassify risk for those in the borderline to intermediate categories. For these patients, a CAC score of zero can provide reassurance, potentially de-escalating their risk and allowing for a more conservative approach to statin therapy. Conversely, a high CAC score in this group could reclassify them into a higher-risk category, prompting the initiation or intensification of preventive treatments like statins. "For patients at borderline risk, knowing their calcium score can help determine whether their risk is actually lower or higher than initially estimated, which can help guide treatment decisions," Shah explained. This individualized approach aligns perfectly with the principles of personalized medicine, ensuring that intensive interventions are reserved for those who stand to benefit most, while avoiding unnecessary tests and treatments for others.
Accurately identifying a person’s risk is fundamental to effective prevention. Cardiovascular disease remains the nation’s leading cause of death, but many heart attacks, strokes, and other cardiovascular events are largely preventable through lifestyle modifications and appropriate pharmacological interventions. Tools like PREVENT and, when used strategically, CAC scans, help doctors determine who is most likely to benefit from preventive treatments, particularly statins, which are highly effective in lowering cholesterol and reducing cardiovascular risk. "The findings help us understand how best to use the available tools to estimate someone’s risk of a heart attack or stroke. That provides more precise guidance for who is most likely to benefit from using a statin to help prevent heart disease," Shah affirmed. The study also implicitly validates the robustness of the relatively new PREVENT calculator, demonstrating its strong performance in predicting cardiovascular risk even without the additional data from a calcium scan.
Despite the significant insights gleaned from this study, the researchers acknowledge that additional studies are needed to further refine the application of CAC scores. Future research should focus on how much calcium scores improve PREVENT estimates in specific populations, particularly higher-risk ethnic groups such as South Asian and Filipino adults, who may exhibit different patterns of atherosclerosis or risk factor profiles. More research is also crucial in younger populations, as participants in the MESA study were between ages 45 and 79 when the research began. Understanding the utility and potential long-term implications of CAC screening in younger individuals could inform future guidelines, balancing the benefits of early detection against concerns regarding lifetime radiation exposure. Furthermore, comprehensive cost-effectiveness analyses would be valuable to fully integrate these findings into public health recommendations and healthcare policies.
In conclusion, the Northwestern Medicine study offers a refined and more nuanced perspective on the utility of coronary artery calcium scans. While these scans provide invaluable direct evidence of atherosclerosis, their greatest predictive power, beyond established risk calculators like PREVENT, lies in reclassifying the risk of individuals in the borderline to intermediate categories. This targeted approach promises to optimize patient care by directing resources and interventions to those who will benefit most, minimizing unnecessary testing, radiation exposure, and healthcare costs, and ultimately advancing the goal of effective and personalized cardiovascular prevention.
Other Northwestern co-authors are Xiaoning Huang, Lucia Petito, Norrina Allen, Dr. Philip Greenland and Dr. Sadiya Khan. The study is titled, "Predictive Utility of Coronary Artery Calcium Added to the PREVENT Atherosclerotic Cardiovascular Disease Equations." It was supported by the American Heart Association (grant 24CDA1266732) and the National Heart, Lung, and Blood Institute (contracts 75N92020D00001, HHSN268201500003I, N01-HC-95159, 75N92020D00005, N01-HC-95160, 75N92020D00002, N01-HC-95161, 75N92020D00003, N01-HC-95162, 75N92020D00006, N01-HC-95163, 75N92020D00004, N01-HC-95164, 75N92020D00007, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168, N01-HC-95169 and grant K23HL157766).
